Searchable abstracts of presentations at key conferences in endocrinology

ea0035p780 | Obesity | ECE2014

Adiposity changes show primacy over the effect of insulin sensitivity changes on androgen profile in obese men integrating short-term weight loss programs

Gama Filipa , Espirito-Santo Raquel , Silva-Nunes Jose , Sabino Teresa , Santos Cristina C , Agapito Ana

Introduction: Several studies point towards lower testosterone levels (TL) in patients with obesity and/or insulin resistance (IR).Aim: To analyze the influence of anthropometric parameters and IR on TL in obese men and weight-dependent changes after a short-term weight loss program.Methods: Data were collected from a group of male patients, aged 18 to 65, when they attended a first obesity appointment and at reassessment 6 months ...

ea0099p522 | Pituitary and Neuroendocrinology | ECE2024

Beyond idiopathic arginine vasopressin deficiency: unveiling its etiology after over a decade

Anton Patricia-Maria , Radian Serban , Cristina Căpăţină , Poiană Cătălina

Introduction: Arginine vasopressin deficiency (AVP-D) is a rare disorder with diverse etiologies. Approximately 30% of cases are labelled idiopathic, often associated with an underlying autoimmune process. This case report presents a previously presumed idiopathic AVP-D, revealing its aetiology after more than a decade of follow-up.Case presentation: A 19-year-old male presented in 2012 with symptoms of AVP-D and non-pruritic papular skin lesions on the ...

ea0090p254 | Thyroid | ECE2023

Endocrine adverse events associated with immune checkpoint inhibitors - A case series

Anne-Marie Stefan Andreea , Iulia-Florentina Burcea , Roxana Ioana Dumitriu , Ramona Dobre , Nicoleta Baculescu , Ionela Baciu , Radian șerban , Cristina Căpățină , Trifanescu Raluca , Poiana Catalina

Background: Immune checkpoint inhibitors (ICIs) are a novel group of drugs, used for treatment of various types of malignancies. The receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) or its ligand (PDL-1) are targeted by those inhibitors. They are associated with immune-related adverse events (irAEs). Endocrinopathies are the most frequent irAEs with a prevalence of approximately 10%. Case study: We retrospect...